Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention
Europace · 2024
DOI: 10.1093/europace/euae245 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Europace, 2024. Verfasst von Jani Thuraiaiyah und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Secondary Prevention, Primary Prevention, Death, Sudden, Cardiac. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
The decisions about placing an ICD in a child are more difficult than in an adult due to longer expected lifespan and the complication risk. Young patients gain the most years from ICDs, despite higher risk of device-related complications. The secondary prevention ICD indication is clear, and device is implanted regardless of potential complications. For primary prevention, risk of sudden cardiac death and complications need to be evaluated. We aimed to compare outcomes for primary and secondary prevention ICDs. Methods and results Retrospective nationwide cohort study including paediatric patients identified from the Danish ICD registry with ICD implanted at an age ≤ 15 from 1982–21. Demographics, complications (composite of device-related infections or lead-failure requiring re-operation, mortality because of arrhythmia, or unknown cause), and mortality were retrieved from medical charts. Endpoint was appropriate therapy (shock or anti-tachycardia pacing for ventricular tachycardia or fibrillation). Of 72 receiving an ICD, the majority had channelopathies (n = 34) or structural heart diseases (n = 28). ICDs were implanted in 23 patients for primary prevention and 49 for secondary prevention, at median ages of 13.8 and 11.6 years (P-value 0.01), respectively. Median follow-up was 9.0 (interquartile ranges: 4.7–13.5) years. The 10-year cumulative incidence of first appropriate therapy was 70%, with complication and inappropriate therapy rates at 41% and 15%, respectively. No difference was observed between prevention groups for all outcomes. Six patients died during follow-up.
Conclusion
In children, two-thirds are secondary prevention ICDs. Children have higher appropriate therapy and complication rates than adults, while the inappropriate therapy rate was low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark.
- Department of Cardiology, Odense University Hospital, Odense, Denmark.
- Department of Paediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
ORCID-Profile: Jani Thuraiaiyah, Berit Thornvig Philbert, Annette Schophuus Jensen, Lucas Yixi Xing, Troels Hoejsgaard Joergensen, Chee Woon Lim, Frederikke Noerregaard Jakobsen, Pernille Steen Bække, Michael Rahbek Schmidt, Morten Holdgaard Smerup, Jens Brock Johansen, Sam Riahi, Jens Cosedis Nielsen, Ole De Backer, Lars Sondergaard, Christian Jons
Zitieren
APA
Thuraiaiyah, J., Philbert, B. T., Jensen, A. S., Xing, L. Y., Joergensen, T. H., Lim, C. W., Jakobsen, F. N., Bække, P. S., Schmidt, M. R., Idorn, L., Holdgaard Smerup, M., Johansen, J. B., Riahi, S., Nielsen, J. C., De Backer, O., Sondergaard, L., & Jons, C. (2024). Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention. Europace. https://doi.org/10.1093/europace/euae245
Vancouver
Thuraiaiyah J, Philbert BT, Jensen AS, Xing LY, Joergensen TH, Lim CW, et al. Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention. Europace. 2024. doi:10.1093/europace/euae245
BibTeX
@article{Thuraiaiyah2024,
author = {Thuraiaiyah, Jani and Philbert, Berit Thornvig and Jensen, Annette Schophuus and Xing, Lucas Yixi and Joergensen, Troels Hoejsgaard and Lim, Chee Woon and Jakobsen, Frederikke Noerregaard and Bække, Pernille Steen and Schmidt, Michael Rahbek and Idorn, Lars and Holdgaard Smerup, Morten and Johansen, Jens Brock and Riahi, Sam and Nielsen, Jens Cosedis and De Backer, Ole and Sondergaard, Lars and Jons, Christian},
title = {Implantable cardioverter defibrillator therapy in paediatric patients for primary vs. secondary prevention},
journal = {Europace},
year = {2024},
doi = {10.1093/europace/euae245}
}
EUVIMED